Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study of neoadjuvant and adjuvant nivolumab ± bempegaldesleukin versus standard of care in cisplatin-ineligible muscle-invasive bladder cancer
2018-002676-40Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial in muscle-invasive bladder carcinoma (MIBC) comparing Nivolumab + bempegaldesleukin, Nivolumab monotherapy and Standard of care (no neoadjuvant therapy) (3 arms). Primary endpoint: Pathologic Complete Response (pCR) rate Arm A vs Arm C. Started Feb 2019; status: completed.
02
Drugs
nivolumabbempegaldesleukin
03
Conditions
muscle-invasive bladder carcinoma (MIBC)
Beyond the preview
Go deeper on 2018-002676-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002676-40.